Impact of SARS-CoV-2 Gamma lineage introduction and COVID-19 vaccination on the epidemiological landscape of a Brazilian city.
Epidemiology
Viral infection
Journal
Communications medicine
ISSN: 2730-664X
Titre abrégé: Commun Med (Lond)
Pays: England
ID NLM: 9918250414506676
Informations de publication
Date de publication:
2022
2022
Historique:
received:
02
08
2021
accepted:
24
03
2022
entrez:
23
5
2022
pubmed:
24
5
2022
medline:
24
5
2022
Statut:
epublish
Résumé
The emergence of the Brazilian variant of concern, Gamma lineage (P.1), impacted the epidemiological profile of COVID-19 cases due to its higher transmissibility rate and immune evasion ability. We sequenced 305 SARS-CoV-2 whole-genomes and performed phylogenetic analyses to identify introduction events and the circulating lineages. Additionally, we use epidemiological data of COVID-19 cases, severe cases, and deaths to measure the impact of vaccination coverage and mortality risk. Here we show that Gamma introduction in São José do Rio Preto, São Paulo, Brazil, was followed by the displacement of seven circulating SARS-CoV-2 variants and a rapid increase in prevalence two months after its first detection in January 2021. Moreover, Gamma variant is associated with increased mortality risk and severity of COVID-19 cases in younger age groups, which corresponds to the unvaccinated population at the time. Our findings highlight the beneficial effects of vaccination indicated by a pronounced reduction of severe cases and deaths in immunized individuals, reinforcing the need for rapid and massive vaccination.
Sections du résumé
Background
UNASSIGNED
The emergence of the Brazilian variant of concern, Gamma lineage (P.1), impacted the epidemiological profile of COVID-19 cases due to its higher transmissibility rate and immune evasion ability.
Methods
UNASSIGNED
We sequenced 305 SARS-CoV-2 whole-genomes and performed phylogenetic analyses to identify introduction events and the circulating lineages. Additionally, we use epidemiological data of COVID-19 cases, severe cases, and deaths to measure the impact of vaccination coverage and mortality risk.
Results
UNASSIGNED
Here we show that Gamma introduction in São José do Rio Preto, São Paulo, Brazil, was followed by the displacement of seven circulating SARS-CoV-2 variants and a rapid increase in prevalence two months after its first detection in January 2021. Moreover, Gamma variant is associated with increased mortality risk and severity of COVID-19 cases in younger age groups, which corresponds to the unvaccinated population at the time.
Conclusions
UNASSIGNED
Our findings highlight the beneficial effects of vaccination indicated by a pronounced reduction of severe cases and deaths in immunized individuals, reinforcing the need for rapid and massive vaccination.
Identifiants
pubmed: 35603276
doi: 10.1038/s43856-022-00108-5
pii: 108
pmc: PMC9053258
doi:
Types de publication
Journal Article
Langues
eng
Pagination
41Informations de copyright
© The Author(s) 2022.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare no competing interests.
Références
Cell. 2021 May 27;184(11):2939-2954.e9
pubmed: 33852911
Viruses. 2020 Oct 09;12(10):
pubmed: 33050264
PLoS Negl Trop Dis. 2018 May 29;12(5):e0006525
pubmed: 29813061
N Engl J Med. 2021 Apr 15;384(15):1412-1423
pubmed: 33626250
Arch Virol. 2012 Nov;157(11):2061-73
pubmed: 22777179
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Mol Biol Evol. 2015 Jan;32(1):268-74
pubmed: 25371430
J Virol. 2005 Jan;79(2):853-9
pubmed: 15613313
Glob Chall. 2017 Jan 10;1(1):33-46
pubmed: 31565258
Nat Methods. 2017 Jun;14(6):587-589
pubmed: 28481363
Lancet. 2021 Jun 19;397(10292):2331-2333
pubmed: 34090624
Nat Commun. 2020 Nov 26;11(1):6013
pubmed: 33243994
Nature. 2021 Apr;592(7852):116-121
pubmed: 33106671
J Virol. 2012 Feb;86(3):1853-61
pubmed: 22130539
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
Viruses. 2021 Jun 26;13(7):
pubmed: 34206727
N Engl J Med. 2021 Jun 10;384(23):2187-2201
pubmed: 33882225
Clin Epidemiol Glob Health. 2021 Jan-Mar;9:157-161
pubmed: 32869006
Nat Med. 2021 Apr;27(4):622-625
pubmed: 33654292
Cell. 2021 Apr 29;184(9):2384-2393.e12
pubmed: 33794143
J Virol. 2012 Jun;86(11):6075-83
pubmed: 22438558
Virology. 1997 Apr 14;230(2):244-51
pubmed: 9143280
Lancet. 2021 May 8;397(10286):1725-1735
pubmed: 33901423
BMJ. 2021 Mar 9;372:n579
pubmed: 33687922
Lancet Glob Health. 2021 Nov;9(11):e1508-e1516
pubmed: 34678195
Cell Host Microbe. 2021 May 12;29(5):747-751.e4
pubmed: 33887205
Science. 2021 May 21;372(6544):815-821
pubmed: 33853970
Rev Inst Med Trop Sao Paulo. 2021 Apr 23;63:e36
pubmed: 33909850
Virus Evol. 2021 Jul 30;7(2):veab064
pubmed: 34527285
Nature. 2021 Apr;592(7855):616-622
pubmed: 33567448
Lancet Microbe. 2021 Oct;2(10):e527-e535
pubmed: 34258603
Cell. 2021 Apr 29;184(9):2348-2361.e6
pubmed: 33730597
Genome Res. 1998 Mar;8(3):186-94
pubmed: 9521922
Science. 2021 Jan 15;371(6526):288-292
pubmed: 33293339
Cell. 2021 Apr 15;184(8):2201-2211.e7
pubmed: 33743891
Science. 2020 Sep 4;369(6508):1255-1260
pubmed: 32703910
Cell Res. 2021 Jun;31(6):720-722
pubmed: 33893398
Nat Med. 2021 Jul;27(7):1230-1238
pubmed: 34035535
Nat Med. 2021 May;27(5):790-792
pubmed: 33782619
Nat Med. 2021 Apr;27(4):717-726
pubmed: 33664494
N Engl J Med. 2021 May 20;384(20):1899-1909
pubmed: 33951374
Sci Transl Med. 2011 Dec 21;3(114):114ra128
pubmed: 22190239
Proc Natl Acad Sci U S A. 2021 Jul 6;118(27):
pubmed: 34140350
Commun Med (Lond). 2022 Apr 13;2:41
pubmed: 35603276
Virus Evol. 2016 Apr 09;2(1):vew007
pubmed: 27774300
Brief Bioinform. 2019 Jul 19;20(4):1160-1166
pubmed: 28968734
Syst Biol. 2006 Aug;55(4):539-52
pubmed: 16785212
Lancet. 2021 May 15;397(10287):1819-1829
pubmed: 33964222
Pathogens. 2021 May 17;10(5):
pubmed: 34067881
N Engl J Med. 2021 May 20;384(20):1885-1898
pubmed: 33725432
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Nature. 2021 May;593(7857):130-135
pubmed: 33684923